PDA

View Full Version : Who is making a swine flu vaccine! How did this virus get legs?



Momtezuma Tuatara
27-04-09, 08:09 AM
Remember this?

http://www.torontosun.com/news/canada/2009/02/27/8560781.html



Baxter: Product contained live bird flu virus

By Helen Branswell, THE CANADIAN PRESS
Last Updated: 27th February 2009, 3:26pm

The company that released contaminated flu virus material from a plant in Austria confirmed Friday that the experimental product contained live H5N1 avian flu viruses.

And an official of the World Health Organization’s European operation said the body is closely monitoring the investigation into the events that took place at Baxter International’s research facility in Orth-Donau, Austria.
“At this juncture we are confident in saying that public health and occupational risk is minimal at present,” medical officer Roberta Andraghetti said from Copenhagen, Denmark.

“But what remains unanswered are the circumstances surrounding the incident in the Baxter facility in Orth-Donau.”

The contaminated product, a mix of H3N2 seasonal flu viruses and unlabelled H5N1 viruses, was supplied to an Austrian research company. The Austrian firm, Avir Green Hills Biotechnology, then sent portions of it to sub-contractors in the Czech Republic, Slovenia and Germany.

The contamination incident, which is being investigated by the four European countries, came to light when the subcontractor in the Czech Republic inoculated ferrets with the product and they died. Ferrets shouldn’t die from exposure to human H3N2 flu viruses.

Public health authorities concerned about what has been described as a “serious error” on Baxter’s part have assumed the death of the ferrets meant the H5N1 virus in the product was live. But the company, Baxter International Inc., has been parsimonious about the amount of information it has released about the event.

On Friday, the company’s director of global bioscience communications confirmed what scientists have suspected.

“It was live,” Christopher Bona said in an email.

The contaminated product, which Baxter calls “experimental virus material,” was made at the Orth-Donau research facility. Baxter makes its flu vaccine — including a human H5N1 vaccine for which a licence is expected shortly — at a facility in the Czech Republic.

People familiar with biosecurity rules are dismayed by evidence that human H3N2 and avian H5N1 viruses somehow co-mingled in the Orth-Donau facility. That is a dangerous practice that should not be allowed to happen, a number of experts insisted.

Accidental release of a mixture of live H5N1 and H3N2 viruses could have resulted in dire consequences.

While H5N1 doesn’t easily infect people, H3N2 viruses do. If someone exposed to a mixture of the two had been simultaneously infected with both strains, he or she could have served as an incubator for a hybrid virus able to transmit easily to and among people.

That mixing process, called reassortment, is one of two ways pandemic viruses are created.

There is no suggestion that happened because of this accident, however.
“We have no evidence of any reassortment, that any reassortment may have occurred,” said Andraghetti.

“And we have no evidence of any increased transmissibility of the viruses that were involved in the experiment with the ferrets in the Czech Republic.”

Baxter hasn’t shed much light — at least not publicly — on how the accident happened. Earlier this week Bona called the mistake the result of a combination of “just the process itself, (and) technical and human error in this procedure.”

He said he couldn’t reveal more information because it would give away proprietary information about Baxter’s production process.
Andraghetti said Friday the four investigating governments are co-operating closely with the WHO and the European Centre for Disease Control in Stockholm, Sweden.

“We are in very close contact with Austrian authorities to understand what the circumstances of the incident in their laboratory were,” she said.
“And the reason for us wishing to know what has happened is to prevent similar events in the future and to share lessons that can be learned from this event with others to prevent similar events. ... This is very important.”

well, lookee here:

http://www.wqad.com/news/sns-ap-il--swineflu-baxter,0,3115984.story (http://www.wqad.com/news/sns-ap-il--swineflu-baxter,0,3115984.story)





Illinois-based Baxter working on vaccine to stop swine flu outbreak in Mexico
By Associated Press

9:22 PM CDT, April 25, 2009

DEERFIELD, Ill. (AP) — Specialty drug maker Baxter International Inc. will work with the World Health Organization to develop a vaccine that could stem an outbreak of a deadly swine flu strain in Mexico.

Baxter spokesman Christopher Bona said Saturday that the Deerfield, Ill.-based company has asked the WHO for a sample of the flu strain.

He says Baxter has patented technology that allows the company to develop vaccines in half the time it usually takes — about 13 weeks instead of 26.

There have been 20 confirmed deaths in Mexico of the swine flu, with nonfatal cases also confirmed in Kansas and California.

Humans don't have a natural immunity to swine flu strain that emerged in Mexico in March. Officials have warned the outbreak could become a global epidemic.

Momtezuma Tuatara
27-04-09, 08:47 AM
A friend emailed me this:


Receptor Specificity and Host Adaptation of Recent Swine
Influenza Viruses
Primary Author:
Shobana Raghunath (shoba@vt.edu (shoba@vt.edu))
Biomedical and Veterinary Sciences
Virginia-Maryland Regional College of Veterinary Medicine
Secondary Authors:
Laure Deflube (ladeflub@vt.edu (ladeflub@vt.edu))
Biomedical and Veterinary Sciences
Thomas Rogers-Cottrone (trogersc@vt.edu (trogersc@vt.edu))
Biomedical and Veterinary Sciences
Dan Qiao (qiao@vt.edu (qiao@vt.edu))
Biomedical and Veterinary Sciences
Vrushali Chavan (vrushali@vt.edu (vrushali@vt.edu))
Biomedical and Veterinary Sciences
Elankumaran Subbiah (kumarans@vt.edu (kumarans@vt.edu))
Biomedical Sciences and Pathobiology

Influenza A viruses (IAV) are generally host specific and they rarely establish stable lineages in another species. Although whole viruses may rarely transmit, gene segments can reassort and viruses cross the species barrier. However, swine influenza A viruses (SIV) have established stable genetic lineages in turkeys in the United States in recent years. Despite their uniform ability to bind to oligosaccharide-containing sialic acids, IAVs show differences in receptor specificity. The preferential binding to ?-2, 3 (avian) or ?-2, 6 (swine and human)-linked oligosaccharides can be altered by changes in HA-specific amino acids that influence both host specificity and cell tropism.

To identify the minimal amino acid changes involved in receptor specificity and efficient transmission of SIV to turkeys, we have sequentially passaged five recent triple reassortant H3N2 SIV isolates from Minnesota in nine to 11 day-old specific-pathogen-free turkey embryos. Complete nucleotide sequencing of the PB1, HA and NA genes before and after each passage was undertaken to identify the host-adapted changes in the antigenic sites and host specific amino acids. We showed that virus replication in turkey embryos leads to mutations in the HA gene of SIVs that are similar to those found in triple reassortant turkey H3N2 viruses. Glycan-HA interactions in the respiratory epithelial cells of swine and turkeys was analyzed. Homology modeling of HA1 proteins indicated a switch in the glycan topology from the open umbrella structure to the cone form after passaging the viruses in turkey embryos. Our results suggest that turkey embryos could serve as an alternative model to study virus evolution and interspecies transmission of SIVs.

so who else has been tinkering around with combinations?

How did this "unique" virus, never before seen suddenly hit ground???

deesalie
27-04-09, 09:17 AM
Gotta keep business booming, ya know! :eyeroll:

passionatewriter
28-04-09, 01:07 PM
this is even scarier than the media fear mongering.